CN Patent

CN102702070A — 包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途

Assigned to Celgene Corp · Expires 2012-10-03 · 14y expired

What this patent protects

本发明公开了包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、包含该固体形式的组合物、制备该固体形式的方法、及其使用方法。该方法包括可通过降低TNF-α水平或抑制PDE4来改善的病症的治疗和/或预防方法。

USPTO Abstract

本发明公开了包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、包含该固体形式的组合物、制备该固体形式的方法、及其使用方法。该方法包括可通过降低TNF-α水平或抑制PDE4来改善的病症的治疗和/或预防方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN102702070A
Jurisdiction
CN
Classification
—
Expires
2012-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.